Frost & Sullivan Independent Equity Research
BioLineRx Ltd.: Continued execution of multiple clinical development programs for the Company’s lead project – BL-8040; Investment by a principal investor reflects confidence in the company’s strategy. Target Price unchanged.
![bioline bioline](https://www.frostequityresearch.com/wp-content/uploads/elementor/thumbs/bioline-nx7oepmjwr0nqu046yc3t5fs9jyo1sg30b9j97eohk.png)
Company: BioLineRx
Sector: Pharmaceuticals
Report type: Quarterly Update
For all past reports click here
Published on: September 6th 2017